ArticleFrontiers in medicine2025
COVID-19 inactivated booster vaccines elicit strong protection against SARS-CoV-2 wild-type and Omicron variant in patients with breast cancer.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with breast cancer are at an increased risk of severe COVID-19 and related mortality. However, the ability of inactivated vaccine-induced antibodies to neutralize both SARS-CoV-2 and its Omicron variant following a third SARS-CoV-2 vaccine dose remains unclear in these patients. Methods: Blood samples from 211 breast cancer patients and 155 healthy controls were analyzed after one, two, or three doses of the inactivated SARS-CoV-2 vaccine. Levels of total anti-SARS-CoV-2 antibodies, anti-receptor binding domain (RBD) IgG, and neutralizing antibodies (NAbs) against both the SARS-CoV-2 wild-type virus and the BA.4/BA.5 (Omicron) variant, along with lymphocyte subsets, were measured 2 weeks to 3 months and more than 6 months after the second and third vaccinations, respectively. Results: Levels of anti-RBD IgG and NAb inhibition rates against both the SARS-CoV-2 wild-type virus and the BA.4/BA.5 (Omicron) variant were significantly higher in breast cancer patients after the third dose than after the second dose. However, these levels remained lower than those observed in healthy controls. Univariate analysis revealed that >6 months after receiving two or three doses was associated with undetectable NAbs against the SARS-CoV-2 wild-type virus compared to those at 2 weeks to 3 months. Additionally, patients aged 60 years or older were correlated with undetectable NAbs against the BA.4/BA.5 (Omicron) variant. Immune responses after two or three doses were not affected by endocrine therapy, either current therapy or vaccination. In particular, univariate and multivariate analyses revealed that the vaccination of breast cancer patients with CoronaVac resulted in significantly higher NAb inhibition rates against the SARS-CoV-2 wild-type virus than BBIBP-CorV. Conclusion: Breast cancer patients boosted with a third dose of inactivated vaccines demonstrated the potent neutralization of SARS-CoV-2 and the Omicron variant compared to receiving one or two doses. Vaccination-mediated NAb induction was affected by age, time > 6 months after vaccination, vaccine type, and cancer-targeted treatment. Therefore, the study results indicated an urgent need for caution and additional strategies to protect these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.